IPH4502 (Nectin-4 exatecan ADC) is an Innate Pharma SA program in solid tumors.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Solid tumors. Sponsor: Innate Pharma SA (IPHA). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
No upcoming catalyst is on our calendar for IPH4502 (Nectin-4 exatecan ADC); no FDA decisions are on record below.
No FDA decision for IPH4502 (Nectin-4 exatecan ADC) is in our archive yet.
In our records IPH4502 (Nectin-4 exatecan ADC) is under review or in development for Solid tumors.
Innate Pharma SA (IPHA).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.